

**‘Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5’**

By Simon J Freeley, Reena J Popat, Kiran Parmar, Martin Kolev, Beverley J Hunt, Cordula M Stover, Wilhelm Schwaeble, Claudia Kemper and Michael G Robson, *J Pathol* 2016; **240**: 61–71. DOI: 10.1002/path.4754

The corresponding author has informed the editors of an error in the ‘Materials and methods’ section of this article, first published on 28 May 2016 in Wiley Online Library (wileyonlinelibrary.com).

In the paragraph entitled ‘Induction of anti-MPO crescentic glomerulonephritis’, the type of lipopolysaccharide (LPS) used in the experimental model was described as “from *E. coli* serotype 0111 B4; Enzo Life Sciences, Exeter, UK”.

The correct description is “from *Escherichia coli* R515; Enzo Life Sciences, UK – catalogue number ALX-581-007-L002”.

The authors apologize for the error and the inconvenience caused.